Skip to main content

Table 1 Immune-related adverse events in melanoma patients <65 and >65 treated with nivolumab.

From: Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma

irAE Incidence (%) Age <65 Incidence (%) Ageā‰„65 p-value
Rash 38.5 40.4 0.966
Diarrhea 30.2 21.2 0.322
Vitilligo 10.4 7.7 0.805
Hypothyroidism 8.3 5.8 0.811
Muscositis 5.2 5.8 0.99
Myalgias 4.2 0 0.336
Pneumonitis 1.1 1.9 0.99